CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Akebia
Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company
focused on delivering innovative therapies to patients with kidney
disease through the biology of hypoxia-inducible factor (HIF), today
announced that the company granted three newly hired employees options
to purchase an aggregate of 9,000 shares of Akebia's common stock with a
per share exercise price of $13.18, the closing price on the grant date.
These options will vest as to 25% of the total number of shares subject
to the option on the first anniversary of the grant date. The remaining
75% of shares will vest ratably on the first day of each calendar
quarter over the next three years. The stock options were inducements
material to these new employees entering into employment with the
company, and issued in reliance on NASDAQ Listing Rule 5635(c)(4).
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on delivering innovative therapies
to patients with kidney disease through hypoxia-inducible factor
biology. Akebia's lead product candidate, vadadustat, is an oral
investigational therapy in development for the treatment of anemia
related to chronic kidney disease in both non-dialysis and dialysis
patients. Akebia's global Phase 3 program for vadadustat, which includes
the PRO2TECT studies for non-dialysis patients with anemia
associated with chronic kidney disease and the INNO2VATE
studies for dialysis-dependent patients, is currently ongoing. For more
information, please visit our website at www.akebia.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170504005278/en/
Akebia
Theresa McNeely, 617-844-6113
SVP, Corporate
Communications
and Investor Relations
tmcneely@akebia.com
Source: Akebia Therapeutics, Inc.
News Provided by Acquire Media